StoxRainbow Childrens Medicare vs Concord Biotech: share price & financials comparison
NSE: RAINBOW vs CONCORDBIO · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Rainbow Childrens Medicare vs Concord Biotech at a glance
Rainbow Childrens Medicare (RAINBOW) has a market capitalisation of ₹12,639 Cr, against ₹6,618 Cr for Concord Biotech (CONCORDBIO). Over the past year Rainbow Childrens Medicare has returned -10.4%, compared with -12.9% for Concord Biotech. On valuation, Concord Biotech trades at a lower P/E of 23.4 versus 43.2. Rainbow Childrens Medicare earns a higher return on equity (17.0% vs 13.6%). Rainbow Childrens Medicare comes out ahead on size and momentum. Concord Biotech comes out ahead on valuation, profitability, growth and technicals. Across the scored metrics below, Rainbow Childrens Medicare leads on 6 and Concord Biotech on 9. On StoxGud's 10-point checklist, Rainbow Childrens Medicare scores 7/10 and Concord Biotech scores 6/10.
| Metric | Rainbow Childrens Medicare | Concord Biotech |
|---|---|---|
| Size | ||
| Market cap | ₹12,639 Cr | ₹6,618 Cr |
| Revenue (latest FY) | ₹1,703 Cr | ₹1,055 Cr |
| Net profit (latest FY) | ₹278 Cr | ₹261 Cr |
| Valuation | ||
| P/E | 43.2 | 23.4 |
| P/B | 7.37 | 3.19 |
| Dividend yield | 0.24% | 1.69% |
| Profitability | ||
| Return on equity | 17.0% | 13.6% |
| Net profit margin | 15.2% | 24.1% |
| Operating margin | 31.0% | 34.5% |
| Growth | ||
| Revenue growth (YoY) | +23.2% | +25.1% |
| Net profit growth (YoY) | +9.1% | +11.1% |
| Revenue CAGR (multi-year) | +15.0% | +1.8% |
| Financial health | ||
| Debt to equity | 0.00 | 0.00 |
| Momentum | ||
| 1-month return | -2.1% | -7.0% |
| 1-year return | -10.4% | -12.9% |
| 3-year CAGR | +6.7% | +3.6% |
| Distance from 52W high | -22.2% | -20.3% |
| Technicals | ||
| RSI (14) | 49 | 45 |
| Price vs 200-day avg | -5.8% | -0.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Rainbow Childrens Medicare | Concord Biotech |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 7/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Rainbow Childrens Medicare or Concord Biotech?
Rainbow Childrens Medicare has a market cap of ₹12,639 Cr and Concord Biotech has a market cap of ₹6,618 Cr as of 06 Nov 2026.
Which has a lower P/E, Rainbow Childrens Medicare or Concord Biotech?
Concord Biotech has the lower P/E: Rainbow Childrens Medicare trades at 43.2 and Concord Biotech at 23.4.
Which gave better returns in the last year, Rainbow Childrens Medicare or Concord Biotech?
Rainbow Childrens Medicare did better: Rainbow Childrens Medicare returned -10.4% and Concord Biotech returned -12.9% over one year.
Is Rainbow Childrens Medicare or Concord Biotech a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Rainbow Childrens Medicare scores 7/10 and Concord Biotech scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.